Physician profile
Atef E Ebrhim
NPI 1295990174
$578.06
in general payments reported to CMS, 2019-2025
17 companies · $53.34 in 2025
The $53.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.52 · 2022: $178 · 2023: $159 · 2024: $127 · 2025: $53.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $131.68 | 2022-2023 | |
| Lilly USA, LLC | $49.24 | 2021-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $48.39 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $46.19 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $43.15 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $38.16 | 2022 | |
| Boston Scientific Corporation | $28.81 | 2024 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $26.77 | 2021 | |
| Abbvie INC. | $26.06 | 2023 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $24.19 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.20 | 2025 | Voquezna |
| Shield Therapeutics INC | $18.47 | 2024 | |
| Aimmune Therapeutics, INC. | $17.41 | 2024 | |
| Dexcom, INC. | $17.14 | 2022 | |
| Novo Nordisk INC | $14.60 | 2024 | Rybelsus, Ozempic |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.60 | 2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $13.00 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atef Ebrhim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.